RDHL
RedHill Biopharma Ltd.NASDAQHealthcare$0.83+3.72%ClosedMarket Cap: $2.8M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.34
P/S
0.41
EV/EBITDA
-0.02
DCF Value
$-2.76
FCF Yield
-239.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.3%
Operating Margin
-109.5%
Net Margin
-98.7%
ROE
149.3%
ROA
-36.6%
ROIC
201.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2025 | $2.0M | 60.6% | $-2.2M | $-2.1M | $-1.00 | — |
| Q1 2025 | $2.0M | 60.6% | $-2.2M | $-2.1M | $-1.00 | — |
| Q4 2024 | $2.7M | 67.3% | $-3.1M | $-2.6M | $-1.00 | — |
| FY 2024 | $8.0M | 60.3% | $-14.6M | $-8.3M | $-7.00 | — |
| Q3 2024 | $2.7M | 67.3% | $-3.1M | $-2.6M | $-1.00 | — |
| Q2 2024 | $1.3M | 45.4% | $-4.2M | $-1.5M | $-1.00 | — |
| Q1 2024 | $1.3M | 45.4% | $-4.2M | $-1.5M | $-1.00 | — |
| Q4 2023 | $567.5K | 8.3% | $-6.0M | $-13.5M | $-17.00 | — |
| FY 2023 | $6.5M | 47.0% | $12.6M | $23.9M | $46.00 | — |
| Q3 2023 | $567.5K | 8.3% | $-6.0M | $-13.5M | $-24.00 | — |
| Q2 2023 | $1.8M | 55.1% | $-4.4M | $761.0K | $3.00 | — |
| Q1 2023 | $3.6M | 55.2% | $29.1M | $50.2M | $256.00 | — |